Critical Assessment of Ten-Year Combined Molecular and Epidemiological Norovirus Surveillance of the Noronet Network, 2005–2016
Refereed conference paper presented and published in conference proceedings



摘要Background: Acute gastroenteritis is the second greatest burden of all infectious diseases, and norovirus is responsible for almost one fifth of all cases worldwide. The genus Norovirus is highly diverse and divided
in seven genogroups (G), which are further subdivided in more than 40 genotypes. Therefore, the development of vaccines requires detailed understanding of global genetic diversity of noroviruses. NoroNet is an informal international data sharing network for clinical-, public health-, and food microbiology laboratories and was established in 2002 to study noroviruses and their diversity in relation to human health impact. This study describes trends in epidemiology and diversity based on global NoroNet surveillance data, and gives a future perspective on the global surveillance needs in light of these developments.

Methods: The study analysed n=16636 norovirus sequences with associated epidemiological metadata, shared between 2005 and 2016 through NoroNet by partners from Europe, Asia, Australia, and Africa.

Findings: We show continued global dominance and evolution of specific noroviruses, particularly of genotype GII.4, but with substantial regional differences possibly reflecting differences in epidemiology, susceptibility
or both. These globally circulating GII.4 strains are frequently replaced by new GII.4 variants. For most of the GII.4 variants that emerged after 2005 we were able to detect the variant 2-5 years before the actual emergence.
However, the 2-3 year periodicity of emergence of GII.4 antigenic drift variants has not been observed since 2012. Instead, the GII.4 Sydney 2012 capsid seems to persist through recombination, and we report the emergence of a GII.P16–GII.4 Sydney 2012 recombinant in Asia and Europe. The novel GII.P17-GII.17 that became the predominant genotype in some parts of Asia in 2015, has circulated widely in Europe but did not become the predominant genotype in Europe. There is no licensed norovirus vaccine on the market, but potential candidates have been tested
in phase I and II Clinical trials. This study showed that currently used sequencing protocols rarely include the main antigenic epitopes on the viral capsid, which will become important in view of ongoing vaccine development.

Interpretation: This study highlights the need for sustained norovirus surveillance, including assessment of possible immune escape and evolution by recombination in order to provide a full overview of norovirus epidemiology for future vaccine policy decisions.
著者Miranda de Graaf, Janko van Beek, Martin Chan, Nobuhiro Iritani, Annelies Kroneman, Harry Vennema, Marion Koopmans
會議名稱The 36th Annual Meeting of the American Society for Virology
會議地點University of Wisconsin-Madison
會議論文集題名The 36th Annual Meeting of the American Society for Virology Scientific Program & Abstracts

上次更新時間 2020-11-05 於 10:46